Novo

Novo Nordisk has signed a licensing agreement with Hengrui for the obesity and diabetes drug HRS-1596 and is paying an upfront of $300 million. The deal can reach up to $2.6 billion in milestone payments; Hengrui retains rights in mainland China, Hong Kong, Macau and Taiwan and is entitled to royalties. Novo receives worldwide exclusive rights outside those territories and will explore the potential for once-weekly oral dosing. Hengrui has already obtained approval in China for Phase‑1 studies; closing of the transaction is expected in Q4 2026. » Más en finanzen.net

Novo Nordisk signed a licensing agreement for Hengrui’s drug HRS-1596 and will pay a $300 million upfront; additional payments are milestone‑linked and could raise the deal value to $2.6 billion. Novo gains exclusive rights to develop, manufacture and commercialize worldwide outside mainland China, Hong Kong, Macau and Taiwan, and Hengrui will receive sales‑based royalties. HRS-1596 is being evaluated for once‑weekly oral administration; a Phase 1 study has already been approved in China, and closing of the transaction is expected in Q4 2026. » Más en finanzen.net

At its capital markets day Novo Nordisk announced it aims to bring more than five blockbuster drugs to market by 2030 and to generate over €20 billion in sales from them by 2035. Research data on Cagri-Sema, a new treatment for overweight, attracted attention; a U.S. approval decision is expected in the fourth quarter. Investors demanded more concrete short-term forecasts, after which the stock recently fell about 10% and is down roughly 75% since its 2024 record high. Analysts cut price targets, while competitor Eli Lilly, with faster earnings growth and a significantly higher valuation, continues to gain market share. » Más en handelsblatt.com